Literature DB >> 15724720

Prevalence of hepatitis C in drug users in Flanders: determinants and geographic differences.

C Matheï1, G Robaeys, P van Damme, F Buntinx, R Verrando.   

Abstract

The prevalence of hepatitis C and related risk factors in drug users were compared in two geographic regions in Belgium, the city of Antwerp and the mixed urban-rural area of Limburg. All 310 participants were surveyed and screened for hepatitis B, hepatitis C and HIV. Prevalence rates of anti-HCV, anti-HBc and anti-HIV were 71, 62 and 4% in Antwerp and 46, 21 and 0% in Limburg respectively. Injecting drug use, duration of injecting drug use, work as a commercial sex-worker, originating from Turkey or Northern Africa, marginalization and anti-HBc positivity were identified as independent predictors for hepatitis C infection. In this study an important difference in HCV seroprevalence among drug users in a methadone maintenance programme across two geographic regions in Belgium was demonstrated. This was explained not only by variations in drug-related risk behaviour, but also by differences in sexual risk behaviour and socio-economic status.

Entities:  

Mesh:

Year:  2005        PMID: 15724720      PMCID: PMC2870231          DOI: 10.1017/s0950268804002973

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

1.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

Review 2.  Non-injection drug use and Hepatitis C Virus: a systematic review.

Authors:  Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss
Journal:  Drug Alcohol Depend       Date:  2006-12-15       Impact factor: 4.492

3.  Assessing Local Model Adequacy in Bayesian Hierarchical Models Using the Partitioned Deviance Information Criterion.

Authors:  David C Wheeler; Demarc A Hickson; Lance A Waller
Journal:  Comput Stat Data Anal       Date:  2010-06-01       Impact factor: 1.681

Review 4.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

5.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

6.  Identification of Patients with Hepatitis C Virus Infection in Persons with Background of Intravenous Drug Use: The First Community Announcement-based Study From Iran.

Authors:  Reza Fadaei Nobari; Marjan Meshkati; Behrooz Ataei; Mohammad Reza Yazdani; Kamal Heidari; Nazila Kassaian; Zary Nokhodian; Parisa Shoaei; Majid Yaran; Peyman Adibi
Journal:  Int J Prev Med       Date:  2012-03

7.  Epidemiology of hepatitis C virus (HCV) infection.

Authors:  Theodore Sy; M Mazen Jamal
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

8.  Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study.

Authors:  Patricia A M Kracht; Elisabeth A de Gee; Agnes van der Poel; Marc A M T Verhagen; Andy I M Hoepelman; Esther A Croes; Joop E Arends
Journal:  Harm Reduct J       Date:  2019-07-15

9.  Evaluation of an antigen-antibody "combination" enzyme linked immunosorbent assay for diagnosis of hepatitis C virus infections.

Authors:  E O Odari; N L M Budambula; H Nitschko
Journal:  Ethiop J Health Sci       Date:  2014-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.